Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 10, 2018 | Cabozantinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABOMETYX (DIN 02480840) under ATC L01EX07 CABOZANTINIB. Indications are not published in the Drug Product Database —… | DIN02480840 | approvedsource: Marketed | health-canada-dpd |
| Oct 10, 2018 | Cabozantinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABOMETYX (DIN 02480832) under ATC L01EX07 CABOZANTINIB. Indications are not published in the Drug Product Database —… | DIN02480832 | approvedsource: Marketed | health-canada-dpd |
| Oct 10, 2018 | Cabozantinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABOMETYX (DIN 02480824) under ATC L01EX07 CABOZANTINIB. Indications are not published in the Drug Product Database —… | DIN02480824 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 12, 2018 | Ibritumomab Tiuxetan | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZEVALIN (DIN 02328674) under ATC V10XX02 IBRITUMOMAB TIUXETAN (90Y). Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2018 | Brigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALUNBRIG (DIN 02479230) under ATC L01ED04 BRIGATINIB. Indications are not published in the Drug Product Database —… | DIN02479230 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 27, 2018 | Apalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERLEADA (DIN 02478374) under ATC L02BB05 APALUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02478374 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 18, 2018 | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02473348) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product… | DIN02473348 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 23, 2018 | Olaparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LYNPARZA (DIN 02475219) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see… | DIN02475219 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 30, 2018 | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOMYCIN FOR INJECTION USP (DIN 02464691) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug… | DIN02464691 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 22, 2017 | Olaratumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as LARTRUVO (DIN 02469227) under ATC L01FX10 OLARATUMAB. Indications are not published in the Drug Product Database —… | DIN02469227 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 20, 2017 | Durvalumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMFINZI (DIN 02468816) under ATC L01FF03 DURVALUMAB. Indications are not published in the Drug Product Database — see… | DIN02468816 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 31, 2017 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPADINA (DIN 02462702) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug Product Database — see… | DIN02462702 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 8, 2017 | Midostaurin | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYDAPT (DIN 02466236) under ATC L01EX10 MIDOSTAURIN. Indications are not published in the Drug Product Database — see… | DIN02466236 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2017 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-CAPECITABINE (DIN 02457504) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02457504 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 24, 2017 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as CCP-LETROZOLE (DIN 02459884) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02459884 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 1, 2017 | Pegaspargase | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONCASPAR (DIN 02461900) under ATC L01XX24 PEGASPARGASE. Indications are not published in the Drug Product Database —… | DIN02461900 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 29, 2017 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02438682) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2017 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02459434) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 15, 2017 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-OXALIPLATIN (DIN 02449692) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02449692 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approved |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 31, 2018 | Brigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALUNBRIG (DIN 02479222) under ATC L01ED04 BRIGATINIB. Indications are not published in the Drug Product Database —… | DIN02479222 | approvedsource: Marketed | health-canada-dpd |
| Aug 31, 2018 | Brigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALUNBRIG (DIN 02479214) under ATC L01ED04 BRIGATINIB. Indications are not published in the Drug Product Database —… | DIN02479214 | approvedsource: Marketed | health-canada-dpd |
| Aug 31, 2018 | Brigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALUNBRIG (DIN 02479206) under ATC L01ED04 BRIGATINIB. Indications are not published in the Drug Product Database —… | DIN02479206 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 5, 2018 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-BORTEZOMIB (DIN 02466708) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02466708 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 23, 2018 | Olaparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LYNPARZA (DIN 02475200) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see… | DIN02475200 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2018 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02468239) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02468239 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2018 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02468220) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02468220 | approvedsource: Marketed | health-canada-dpd |
| May 3, 2018 | Inotuzumab Ozogamicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BESPONSA (DIN 02473909) under ATC L01FB01 INOTUZUMAB OZOGAMICIN. Indications are not published in the Drug Product… | DIN02473909 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 27, 2018 | Ribociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KISQALI (DIN 02473569) under ATC L01EF02 RIBOCICLIB. Indications are not published in the Drug Product Database — see… | DIN02473569 | approvedsource: Marketed | health-canada-dpd |
| Apr 24, 2018 | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RITUXAN SC (DIN 02473976) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database —… | DIN02473976 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 19, 2020 |
| health-canada-dpd |
| Dec 18, 2017 | Avelumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BAVENCIO (DIN 02469723) under ATC L01FF04 AVELUMAB. Indications are not published in the Drug Product Database — see… | DIN02469723 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 6, 2017 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPADINA (DIN 02462680) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug Product Database — see… | DIN02462680 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 25, 2017 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-AZACITIDINE (DIN 02463199) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product… | DIN02463199 | withdrawnsource: Cancelled Post Marketsince Jun 27, 2023 | health-canada-dpd |
| Oct 25, 2017 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02462826) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02462826 | approvedsource: Marketed | health-canada-dpd |
| Oct 18, 2017 | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-GEFITINIB (DIN 02468050) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database… | DIN02468050 | approvedsource: Marketed | health-canada-dpd |
| Oct 17, 2017 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION (DIN 02458020) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02458020 | approvedsource: Marketed | health-canada-dpd |
| Oct 4, 2017 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONIVYDE (DIN 02467135) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see… | DIN02467135 | withdrawnsource: Cancelled Post Marketsince Mar 27, 2026 | health-canada-dpd |
| Oct 4, 2017 | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFAN FOR INJECTION (DIN 02463733) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product… | DIN02463733 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 31, 2017 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-CAPECITABINE (DIN 02457490) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02457490 | approvedsource: Marketed | health-canada-dpd |
| Aug 22, 2017 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ERLOTINIB (DIN 02461889) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02461889 | approvedsource: Marketed | health-canada-dpd |
| Aug 22, 2017 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ERLOTINIB (DIN 02461870) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02461870 | approvedsource: Marketed | health-canada-dpd |
| Aug 22, 2017 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ERLOTINIB (DIN 02461862) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02461862 | approvedsource: Marketed | health-canada-dpd |
| Aug 21, 2017 | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLATECT (DIN 02460661) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product… | DIN02460661 | approvedsource: Marketed | health-canada-dpd |
| Aug 1, 2017 | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE INJECTION, USP (DIN 02431130) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug… | DIN02431130 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 3, 2023 |
| health-canada-dpd |
| Jul 24, 2017 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as CCP-ANASTROZOLE (DIN 02458799) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02458799 | withdrawnsource: Cancelled Post Marketsince Aug 3, 2023 | health-canada-dpd |
| Jul 13, 2017 | Pembrolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as KEYTRUDA (DIN 02456869) under ATC L01FF02 PEMBROLIZUMAB. Indications are not published in the Drug Product Database —… | DIN02456869 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 24, 2017 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02438674) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02438674 | approvedsource: Marketed | health-canada-dpd |
| May 2, 2017 | Atezolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECENTRIQ (DIN 02462990) under ATC L01FF05 ATEZOLIZUMAB. Indications are not published in the Drug Product Database —… | DIN02462990 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 31, 2017 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02394227) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02394227 | approvedsource: Marketed | health-canada-dpd |
| Mar 21, 2017 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02452456) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02452456 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Sep 18, 2024 |
| health-canada-dpd |
| Feb 15, 2017 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PEMETREXED (DIN 02429209) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02429209 | approvedsource: Marketed | health-canada-dpd |